Carregant...

Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation

Recently, clinical development of PARP inhibitors (PARPi) expanded from using them as a single agent to combining them with DNA-damaging therapy to derive additional therapeutic benefit from stimulated DNA damage. Furthermore, inhibiting PARP in cancers with BRCA1/2 mutations has been shown to be an...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Redox Biol
Autors principals: Wilson, Aaron, Menon, Vijay, Khan, Zubair, Alam, Asim, Litovchick, Larisa, Yakovlev, Vasily
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6423503/
https://ncbi.nlm.nih.gov/pubmed/30889466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.redox.2019.101169
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!